Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil H Bander

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
The Oncologist|January 31, 2020
Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (<sup>177</sup> Lu-J591) for Metastatic Castration-Resistant Prostate CancerMuhammad Junaid Niaz, Jaspreet S Batra, Ryan D Walsh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2013
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancerScott T Tagawa, Matthew I Milowsky, Michael Morris, et al.
Chemmedchem|July 10, 2008
Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapyAndrew Z Wang, Vaishali Bagalkot, Christophoros C Vasilliou, et al.
Cancer Research|July 30, 2011
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancerMedha S Darshan, Matthew S Loftus, Maria Thadani-Mulero, et al.
Urologic Oncology|July 1, 2020
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (<sup>177</sup>Lu-J591) for metastatic castration-resistant prostate cancerJaspreet S Batra, Muhammad Junaid Niaz, Young E Whang, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 31, 2012
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavityMichael C Haffner, Johannes Laimer, Alcides Chaux, et al.
Plos One|January 4, 2014
Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flowGunjan Gakhar, Vicente N Navarro, Madelyn Jurish, et al.
The Journal of Urology|October 19, 2013
A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomyJoseph R Osborne, David A Green, Daniel E Spratt, et al.
The Journal of Clinical Endocrinology and Metabolism|January 16, 2016
Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical CarcinomaMichael J P Crowley, Theresa Scognamiglio, Yi-Fang Liu, et al.
The Prostate|May 3, 2018
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working groupAndrea K Miyahira, Kenneth J Pienta, Michael J Morris, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
The Oncologist|January 31, 2020
Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (<sup>177</sup> Lu-J591) for Metastatic Castration-Resistant Prostate CancerMuhammad Junaid Niaz, Jaspreet S Batra, Ryan D Walsh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2013
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancerScott T Tagawa, Matthew I Milowsky, Michael Morris, et al.
Chemmedchem|July 10, 2008
Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapyAndrew Z Wang, Vaishali Bagalkot, Christophoros C Vasilliou, et al.
Cancer Research|July 30, 2011
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancerMedha S Darshan, Matthew S Loftus, Maria Thadani-Mulero, et al.
Urologic Oncology|July 1, 2020
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (<sup>177</sup>Lu-J591) for metastatic castration-resistant prostate cancerJaspreet S Batra, Muhammad Junaid Niaz, Young E Whang, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 31, 2012
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavityMichael C Haffner, Johannes Laimer, Alcides Chaux, et al.
Plos One|January 4, 2014
Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flowGunjan Gakhar, Vicente N Navarro, Madelyn Jurish, et al.
The Journal of Urology|October 19, 2013
A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomyJoseph R Osborne, David A Green, Daniel E Spratt, et al.
The Journal of Clinical Endocrinology and Metabolism|January 16, 2016
Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical CarcinomaMichael J P Crowley, Theresa Scognamiglio, Yi-Fang Liu, et al.
The Prostate|May 3, 2018
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working groupAndrea K Miyahira, Kenneth J Pienta, Michael J Morris, et al.
Pageof 9